Letter to the editor We read Ebina and colleagues' article with great interest [1]. Biomarker based classification of Parkinson's disease (PD) subtypes is a recently featured research topic [2], and the authors provided additional insights into the utility of 123I-metaiodobenzylguanidine (MIBG) scintigraphy in the PD subtype classification. However, abnormal MIBG uptake in the major salivary gland, one of their main results, seemed not specific for PD and needs further verification to discuss the pathophysiological implication of MIBG accumulation in the salivary glands.
https://www.jns-journal.com/ar....ticle/S0022-510X(24)